The Experts below are selected from a list of 90 Experts worldwide ranked by ideXlab platform
Serafino Garella - One of the best experts on this subject based on the ideXlab platform.
-
Nonthrombocytopenic Purpura associated sequentially with nifedipine and diltiazem. Ann Pharmacother
1992Co-Authors: Margaret Kuo, Nancy Winiarski, Serafino GarellaAbstract:OBJECTIVE: To report the case of a patient who developed Nonthrombocytopenic Purpura sequentially following the administration of nifedipine and diltiazem. DATA SOURCES: Case reports, MEDLINE review of pertinent literature, and review of relevant studies. DATA EXTRACfiON: Data were extracted from direct patient observation and review of laboratory studies and published reports. DATA SYNTHESIS: Nonthrombocytopenic Purpura secondary to cutaneous vasculitis is a known, although rare,adverse effect of nifedipine. It has not been reported in association with diltiazem. We report the case of a 75-year-old woman in whom a purpuric rash demonstrated by biopsy to be attributable to cutaneous vasculitis developed in the course of nifedipine therapy. The rash disappeared after discontinuation of the drug; however, it recurred when diltiazem therapy was initiated. CONCLUSIONS: Nonthrombocytopenic Purpura may be associated with diltiazem as well as with nifedipine. When this adverse effect occurs following administration of a calcium-channel blocker, caution is advised in using other agents of the same class. Ann Pharmacother 1992;26: 1089-90. CUTANEOUS VASCULITIS, manifested as nonthrombocy-topenic palpable Purpura, has been described as an adverse effect of nifedipine therapy.I·] This adverse effect has also been reported with the use of diltiazem; however, it is questionable whether diltiazem or the patient's illness was responsible for the vasculitis. ' We report the case of a pa-tient who developed palpable Nonthrombocytopenic pur-pura sequentially after the administration of nifedipine and diltiazem
-
Nonthrombocytopenic Purpura Associated Sequentially with Nifedipine and Diltiazem
The Annals of pharmacotherapy, 1992Co-Authors: Margaret Kuo, Nancy Winiarski, Serafino GarellaAbstract:OBJECTIVE:To report the case of a patient who developed Nonthrombocytopenic Purpura sequentially following the administration of nifedipine and diltiazem.DATA SOURCES:Case reports, MEDLINE review of pertinent literature, and review of relevant studies.DATA EXTRACTION:Data were extracted from direct patient observation and review of laboratory studies and published reports.DATA SYNTHESIS:Nonthrombocytopenic Purpura secondary to cutaneous vasculitis is a known, although rare, adverse effect of nifedipine. It has not been reported in association with diltiazem. We report the case of a 75-year-old woman in whom a purpuric rash demonstrated by biopsy to be attributable to cutaneous vasculitis developed in the course of nifedipine therapy. The rash disappeared after discontinuation of the drug; however, it recurred when diltiazem therapy was initiated.CONCLUSIONS:Nonthrombocytopenic Purpura may be associated with diltiazem as well as with nifedipine. When this adverse effect occurs following administration of a...
Bor-luen Chiang - One of the best experts on this subject based on the ideXlab platform.
-
Renal manifestations in Henoch–Schönlein Purpura: a 10-year clinical study
Pediatric Nephrology, 2005Co-Authors: Wen-liang Chang, Yao-hsu Yang, Li-chieh Wang, Yu-tsan Lin, Bor-luen ChiangAbstract:Henoch–Schönlein Purpura (HSP) is an IgA-mediated systemic small vessel vasculitis of childhood. It is characterized by the symptoms including Nonthrombocytopenic Purpura, abdominal pain, hematuria/proteinuria, and arthargia/arthritis. We conducted a retrospective study of 261 patients diagnosed with HSP from December 1991 to December 2001. Of the 261 patients, fifty-three (20.3%) developed renal manifestations after onset of the disease. Two patients developed nephrotic syndrome. Four patients had group A beta-hemolytic streptococcal pharyngitis and subsequent depressed serum C3 concentration typical of post streptococcal glomerulonephritis. During the study period, the renal survival rate after disease onset was 100%. The prognosis of renal involvement was better than reports from other series. In this study we also found factors associated with HSP nephritis; these included older age at onset, GI bleeding, and central nervous system involvement. The long-term morbidity of HSP is predominantly attributed to renal involvement. It is thus recommended that patients with HSP nephritis are followed for longer periods of time.
Margaret Kuo - One of the best experts on this subject based on the ideXlab platform.
-
Nonthrombocytopenic Purpura associated sequentially with nifedipine and diltiazem. Ann Pharmacother
1992Co-Authors: Margaret Kuo, Nancy Winiarski, Serafino GarellaAbstract:OBJECTIVE: To report the case of a patient who developed Nonthrombocytopenic Purpura sequentially following the administration of nifedipine and diltiazem. DATA SOURCES: Case reports, MEDLINE review of pertinent literature, and review of relevant studies. DATA EXTRACfiON: Data were extracted from direct patient observation and review of laboratory studies and published reports. DATA SYNTHESIS: Nonthrombocytopenic Purpura secondary to cutaneous vasculitis is a known, although rare,adverse effect of nifedipine. It has not been reported in association with diltiazem. We report the case of a 75-year-old woman in whom a purpuric rash demonstrated by biopsy to be attributable to cutaneous vasculitis developed in the course of nifedipine therapy. The rash disappeared after discontinuation of the drug; however, it recurred when diltiazem therapy was initiated. CONCLUSIONS: Nonthrombocytopenic Purpura may be associated with diltiazem as well as with nifedipine. When this adverse effect occurs following administration of a calcium-channel blocker, caution is advised in using other agents of the same class. Ann Pharmacother 1992;26: 1089-90. CUTANEOUS VASCULITIS, manifested as nonthrombocy-topenic palpable Purpura, has been described as an adverse effect of nifedipine therapy.I·] This adverse effect has also been reported with the use of diltiazem; however, it is questionable whether diltiazem or the patient's illness was responsible for the vasculitis. ' We report the case of a pa-tient who developed palpable Nonthrombocytopenic pur-pura sequentially after the administration of nifedipine and diltiazem
-
Nonthrombocytopenic Purpura Associated Sequentially with Nifedipine and Diltiazem
The Annals of pharmacotherapy, 1992Co-Authors: Margaret Kuo, Nancy Winiarski, Serafino GarellaAbstract:OBJECTIVE:To report the case of a patient who developed Nonthrombocytopenic Purpura sequentially following the administration of nifedipine and diltiazem.DATA SOURCES:Case reports, MEDLINE review of pertinent literature, and review of relevant studies.DATA EXTRACTION:Data were extracted from direct patient observation and review of laboratory studies and published reports.DATA SYNTHESIS:Nonthrombocytopenic Purpura secondary to cutaneous vasculitis is a known, although rare, adverse effect of nifedipine. It has not been reported in association with diltiazem. We report the case of a 75-year-old woman in whom a purpuric rash demonstrated by biopsy to be attributable to cutaneous vasculitis developed in the course of nifedipine therapy. The rash disappeared after discontinuation of the drug; however, it recurred when diltiazem therapy was initiated.CONCLUSIONS:Nonthrombocytopenic Purpura may be associated with diltiazem as well as with nifedipine. When this adverse effect occurs following administration of a...
C. Di Rocco - One of the best experts on this subject based on the ideXlab platform.
-
Cerebral hemorrhage in Henoch-Schoenlein syndrome
Child’s Nervous System, 2002Co-Authors: Antonio Chiaretti, Elena Caresta, Marco Piastra, S. Pulitanò, C. Di RoccoAbstract:Background. Henoch-Schoenlein syndrome (HSS) is the most common form of vasculitis seen in childhood. The clinical diagnosis is based on the association of Nonthrombocytopenic Purpura, arthritis and abdominal pain. Nephropathy is the most common complication. Hemorrhages can occur in the respiratory, gastrointestinal and urinary tracts. Neurological complications are rare, though they may be particularly severe. Case report and discussion. Intracranial hemorrhage is an extremely rare complication of the disease; we report the case of a child with cerebral hemorrhage in HSS and review the literature.
-
Cerebral hemorrhage in Henoch-Schoenlein syndrome
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2002Co-Authors: Antonio Chiaretti, Elena Caresta, Marco Piastra, S. Pulitanò, C. Di RoccoAbstract:Background.Henoch-Schoenlein syndrome (HSS) is the most common form of vasculitis seen in childhood. The clinical diagnosis is based on the association of Nonthrombocytopenic Purpura, arthritis and abdominal pain. Nephropathy is the most common complication. Hemorrhages can occur in the respiratory, gastrointestinal and urinary tracts. Neurological complications are rare, though they may be particularly severe.
James N. Moy - One of the best experts on this subject based on the ideXlab platform.
-
Atypical presentation of Henoch-Schonlein Purpura: Case report and review of the literature
Journal of Allergy and Clinical Immunology, 2004Co-Authors: J.l. Rubin, James N. MoyAbstract:Abstract Rationale Henoch-Schonlein Purpura (HSP) is a systemic vasculitis primarily affecting children, characterized by Nonthrombocytopenic Purpura and may include joint, gastrointestinal, or renal involvement. Clinical history and a characteristic rash of palpable Purpura concentrated on the lower extremities and buttocks aid in the diagnosis. We report a case of HSP presenting with scalp edema and hemorrhagic vesiculobullous lesions and review of the literature. Methods A 4YO male presented with scalp edema and palpable purpuric lesions on his lower extremities and buttocks. He had an upper respiratory infection (URI) the previous week. Review of systems and exam were otherwise negative. Laboratory tests revealed normal white cell and platelet counts, sedimentation rate, complement, BUN/Cr, urinalysis, and a negative stool hemoccult. He was diagnosed with HSP. One month later he had a URI and knee swelling, followed by a hemorrhagic vesiculobullous eruption over his buttocks and lower extremities. Laboratory evaluation was again unremarkable. Literature review of the cutaneous manifestations in HSP was performed. Results Review of the literature revealed few case reports of either scalp edema or hemorrhagic vesiculobullous lesions in HSP. The documented incidence of vesiculobullous lesions in childhood HSP is only 2-4% (compared to 16% in adult cases). Scalp edema is also uncommon in children over 3YO with HSP. Our patient was 4YO with both features over the course of his illness. Conclusions Scalp edema and hemorrhagic vesiculobullous lesions are uncommon findings in childhood HSP and may be a source of diagnostic confusion. Physicians should recognize such signs as possible manifestations of HSP.
